Results for tag: "Proteus Syndrome Drug"

Proteus Syndrome is a rare genetic disorder that affects the growth of bones, skin, and other tissues. It is caused by a mutation in the AKT1 gene. Treatment for Proteus Syndrome is limited and includes drugs that target the endocrine and metabolic systems. Endocrine and metabolic disorder drugs are used to treat the symptoms of Proteus Syndrome, such as overgrowth of the skin and bones, and to reduce the risk of complications. These drugs can also help to improve the quality of life of those affected by the disorder. The Proteus Syndrome Drug market is composed of a variety of pharmaceutical companies that specialize in the development and production of drugs for endocrine and metabolic disorders. These companies include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are dedicated to providing innovative treatments for Proteus Syndrome and other endocrine and metabolic disorders. Show Less Read more